Latest News and Press Releases

MindRank, artificial intelligence (AI)-empowered drug discovery company, announced FPI in Phase III Trial of an Oral GLP-1 Receptor Agonist MDR-001.

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences

MindRank Initiates Phase III "MOBILE" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI

NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries

Austin, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artificial Intelligence (AI) in Biotechnology Market Size & Growth Analysis According to SNS Insider, the global Artificial Intelligence (AI) in...

Austin, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AI in Precision Medicine Market Size & Growth Analysis According to SNS Insider, the global AI in Precision Medicine Market was valued at USD 1.80...

Ottawa, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The global generative AI in drug discovery market size was valued at USD 250 million in 2024 and is predicted to hit around USD 2847.43 million by 2034,...

Using an optimized once-daily (QD) regimen, MDR-001 achieved a body weight reduction of 8.9% over 12 weeks.

Mindrank delivered a keynote presentation entitled “AI-Designed Oral GLP-1RA: First-in-Class Phase IIb Clinical Readouts and Translational Insights”.

ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies GMP manufacturing of clinical trial batch successfully completed On track for CTA submission in Q4 2025 ...